+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BALPHARMA

Bal Pharma Share Price

 

 

Bal Pharma live price: ₹86.19. It opened at ₹86 vs previous close ₹84; intraday high/low: ₹90/₹84. The 50 & 200 DMA stand at ₹81.18/₹80.94.

Bal Pharma Performance

  • Today's Low
  • ₹84
  • Today's High
  • ₹90
  • 52 Week Low
  • ₹60
  • 52 Week High
  • ₹111
  • Open Price₹86
  • Previous Close₹84
  • Volume70,095
  • 50 DMA₹81.18
  • 100 DMA₹78.75
  • 200 DMA₹80.94

Bal Pharma Chart

Investment Returns

  • Over 1 Month + 6.05%
  • Over 3 Month + 20.56%
  • Over 6 Month + 17.19%
  • Over 1 Year -19.12%

Smart Investing Starts Here Start SIP with Bal Pharma for Steady Growth!

Invest Now

Bal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.8
  • PEG Ratio
  • -1.7
  • Market Cap Cr
  • 137
  • P/B Ratio
  • 1.7
  • Average True Range
  • 5.28
  • EPS
  • 3.95
  • Dividend Yield
  • 1.4
  • MACD Signal
  • 2.49
  • RSI
  • 53.5
  • MFI
  • 66.03

Latest Stock News Updates

Bal Pharma Standalone September 2023 Net Sales at Rs 92.30 crore, up 22.98% Y-o-Y

Bal Pharma Consolidated March 2023 Net Sales at Rs 82.45 crore, up 11.35% Y-o-Y

Bal Pharma Consolidated September 2022 Net Sales at Rs 75.31 crore, up 12.11% Y-o-Y

NULL

Bal Pharma Financials

Bal Pharma Technicals

EMA & SMA

Current Price
₹86.19
+ 2.07 (2.46%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹85.20
  • 50 Day
  • ₹81.20
  • 100 Day
  • ₹78.80
  • 200 Day
  • ₹80.90

Resistance and Support

86.84 Pivot Speed
  • R3 94.98
  • R2 92.48
  • R1 89.34
  • S1 83.70
  • S2 81.20
  • S3 78.06

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bal Pharma has an operating revenue of Rs. 311.66 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 2% needs improvement, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 8% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 61 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-27 Audited Results, Final Dividend & ESOP
2026-02-11 Quarterly Results
2025-11-12 Quarterly Results
2025-08-11 Quarterly Results, ESOP & A.G.M.
2025-05-29 Audited Results & Dividend
Date Purpose Remarks
2025-09-18 FINAL Rs.1.20 per share(12%)Dividend
View Bal Pharma Dividend History Arrow

Bal Pharma Shareholding Pattern

50.86%
0.14%
32.84%
16.16%

Bal Pharma FAQs

Bal Pharma share price is ₹86 As on 13 June, 2026 | 20:19

The Market Cap of Bal Pharma is ₹137.2 Cr As on 13 June, 2026 | 20:19

The P/E ratio of Bal Pharma is 21.8 As on 13 June, 2026 | 20:19

The PB ratio of Bal Pharma is 1.7 As on 13 June, 2026 | 20:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23